Wortmannin

For research use only. Not for use in humans.

Catalog No.S2758 Synonyms: KY 12420

109 publications

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Wortmannin has been cited by 109 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjwV|FKOi53IN88US=> MnXUNU01KGR? M{[5fWROW09? M4\hZ4VvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25idILlZZRu\W62IIfpeIghfGGvb4jp[oVv M37lWFI2PDlyM{iz
H1703 NH\yZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDKPGhbOi53IN88US=> M4PGTVEuPCCm MVjEUXNQ NI\vZnVmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIITy[YF1dWWwdDD3bZRpKHSjbX;4bYZmdg>? NF3CN28zPTR7MEO4Ny=>
HUVECs MUjDfZRwfG:6aXPpeJkhSXO|YYm= M3SyO|ExOCCwTR?= MXKyOEBp NEPBRplifHSnboXheIV{KHSqZTDhZpJw\2G2aY\lJIVn\mWldIOgc4Yh[2GueXPvd4lvKG:wIG\STU1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NGrCWFIzPTR3MEG4Oi=>
APRE-19 NGe5e4pCeG:ydH;zbZMhSXO|YYm= M2jKWFUh|ryP MXGyOEBp M4m4W4Fjd2yrc3jld{BHVFpvbXXkbYF1\WRicILvMZN2en[rdnHsM4FvfGlvYYDvdJRwe2m|IHHjeIl3cXS7 MmTHNlU{Ojl4MUe=
MDA-MB-231 NHP0XG9CeG:ydH;zbZMhSXO|YYm= NHHhWW0yyqEQvF5CpC=> MXW0PEBp M3\sTWROW09? M2PlXoRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEB1emWjdHXkJJdqfGhiMkWg{txOKG:oIF[xJI9zKEZ{INMg MljXNlU{ODB7M{K=
MCF7 MnG2SpVv[3Srb36gRZN{[Xl? M1G1[VExOCCwTR?= NH:wO4wzPCCq MlzF[YxqdWmwYYTld{BGOi2rbnT1Z4VlKEGURT3MeYMh[WO2aY\peJk> M4LZb|I2OTd{NUW3
HT-29  NXrYNHFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L5UlEvPcLiwsXN NGTrSVE6PiCq NUnLN4Zl\GWlcnXhd4V{KGOnbHyg[5Jwf3SqIIfobYNpKGOjbjDi[UBqdmirYnn0[YQh[nliS2nORS=> NWHDdnNGOjVyMUKxNlM>
MO59K  MVrDfZRwfG:6aXPpeJkhSXO|YYm= NX\KdHI1PcLizszN NV\MdXJxPyCm NYToe|NkTE2VTx?= MmO0[Y5p[W6lZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw M1nlWVI1QTV|NU[x
MO59J MorER5l1d3SxeHnjbZR6KEG|c3H5 NHWySVI2yqEQvF2= NXXicllGPyCm NH24d|BFVVOR MU\lcohidmOnczD0bIUh[3m2b4TvfIlkcXS7IH;mJIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? NUDUR3M6OjR7NUO1OlE>
MO59K  M1HIUGFxd3C2b4Ppd{BCe3OjeR?= NYmzWFZxOTBizszN NVvpXGdMOjRiaB?= MYrEUXNQ MUjpcoNz\WG|ZYOgeIhmKESVQjDs[ZZmdCCrbnT1Z4VlKGK7IHX0c5Bwe2mmZTDvdkBkcXOybHH0bY4> NYfXVnNiOjR7NUO1OlE>
MO59J NFjPUoZCeG:ydH;zbZMhSXO|YYm= M3PMeVExKM7:TR?= MU[yOEBp NULZToE3TE2VTx?= NF;DW2hqdmO{ZXHz[ZMhfGinIFTTRkBt\X[nbDDpcoR2[2WmIHL5JIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? NUnGfVdJOjR7NUO1OlE>
HepG2 NWnv[2JLTnWwY4Tpc44hSXO|YYm= NH;F[ooyODBibl2= NXnkUmJiOC53IHi= MX;EUXNQ NFToeGFjdG:la4OgUWEucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v NWLhRm05OjR6NkOzOVA>
A549  M{TuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXKfZY{KML3TdMg NX3t[lRpOiCq NXzFcotGe3WycILld5NmeyCyZX3leJJmgGWmLXnu[JVk\WRiQXv0JIFv\CCJU1uz{tIh[WO2aY\heIlwdixiUz3wbIF{\SCjcoLld5QtKGOnbHygZZBweHSxc3nzJIFv\CClYYPwZZNmNTNiYXP0bZZifGmxbh?= MVGyOFg1Pzh4Mx?=
A549  NYCzb4xbTnWwY4Tpc44hSXO|YYm= NX7Le|hyOTEEoN88ceKh M{j1dlE3KGh? MmqxSG1UVw>? MXvtc4R2dGG2ZYOgeIhmKEmDVjDy[ZBtcWOjdHnvckBidmRiY3H1d4V{KHKndHXueIlwdiCxZjDOVEBqdiC2aHWgcpVkdGW3cz6= NY\kO4E1OjR6MEKxNVE>
SK-N-LO NGPhcVVHfW6ldHnvckBCe3OjeR?= M3GwflExOCCwTR?= MXmwMlUhcA>? NGDlOVhl\WO{ZXHz[ZMhfGinIIP0bY12dGGwdDDl[oZm[3S|IH;mJI1wenCqaX7lJI9vKEGtdDDwbI9{eGixconsZZRqd25? MXSyOFY2PDZyNh?=
HL-60 MYDGeY5kfGmxbjDBd5NigQ>? NUPwNll4OC5zwrFOwG0> Mkm0O|IhcA>? MWnicI9kc3NiZHHzZZRqdmmkLXnu[JVk\WRiY3XscEBlcW[oZYLlcpRq[XSrb36= NHn6bYIzPDZyN{K3Ny=>
HepG2  NXPZUIFmTnWwY4Tpc44hSXO|YYm= NETDdJIzODBibl2= NVTkZmlvOC53IHi= MWDheJRmdnWjdHXzJGZwgE9icHjvd5Bpd3K7bHH0bY9v Mm\XNlQ2OzVzOUK=
H520 MY\GeY5kfGmxbjDBd5NigQ>? MoPUNVDDqM7:TR?= NH36PIwyKGh? M3rCcGROW09? MkDS[IVkemWjc3XzJINmdGy3bHHyJJBpd3OyaH:tRWtVKHC{b4TlbY4hdGW4ZXzz Mnj3NlQ1PDd7M{W=
H1975 MUTGeY5kfGmxbjDBd5NigQ>? MW[xNOKh|ryP MWGxJIg> NWLx[nVDTE2VTx?= NIjCO4tl\WO{ZXHz[ZMh[2WubIXsZZIheGixc4Doc{1CU1RicILveIVqdiCuZY\lcJM> MUeyOFQ1Pzl|NR?=
MG-63 MV;BdI9xfG:|aYOgRZN{[Xl? MXKxNEDDvU1? M17HblEzKGh? Mmm1[Y5p[W6lZYOgSHAucW6mdXPl[EBieG:ydH;zbZM> M2DDclI1OzV6M{Cx
5637 MXPBdI9xfG:|aYOgRZN{[Xl? NIjncYUyOMLizszN NEnRN401OCCvaX6= Ml;ZdoV3\XK|ZYOgdFIyX0GIMTDlfJBz\XO|aX;uMEBETEtiZYjwdoV{e2mxbjygZY5lKGOnbHygbY5pcWKrdHnvckBqdmS3Y3XkJIJ6KG[3Y3;p[IFv M33TfFI1OzN|OE[4
HEK-293 NF21d|RHfW6ldHnvckBCe3OjeR?= MmP1NVUxdk1? MojGNVYhcA>? NWDNZldITE2VTx?= MVHk[YNz\WG|ZYOgR3JVKGGldHn2bZR6 M2n6eFI1OzJ2M{[2
SW480  NV\IVYNGTnWwY4Tpc44hSXO|YYm= MUCxOVBvVQ>? M3\GXFIxKGh? M1XDUGROW09? M2m4dJJm\HWlZYOgZ4VtdHWuYYKgZYNkfW23bHH0bY9vKG:oIN8yMYNifGWwaX6= MYeyOFMzPDN4Nh?=
HepG2 MnHvSpVv[3Srb36gRZN{[Xl? MkfFNVAxKG6P MVGyOEBp NVHk[mJ[[XS2ZX71ZZRmeyC2aHWgZ49td26rZYOgc4YhfGinIIT1cY9zKGOnbHzzJJdqfGhidYDy[Yd2dGG2aX;uJI9nKEGtdEG= NILrd4EzPDJ7N{WxNC=>
HCT 116  MnzWSpVv[3Srb36gRZN{[Xl? MlvSNVAxKG6P MVyyOEBp M{\Jc4F1fGWwdXH0[ZMhfGinIHPvcI9vcWW|IH;mJJRp\SC2dX3vdkBk\WyuczD3bZRpKHWycnXneYxifGmxbjDv[kBCc3Rz MnHaNlQzQTd3MUC=
BEL/FU M4TLOGZ2dmO2aX;uJGF{e2G7 NGn2N2gyKG2P MkLSNlQhcA>? NGnoW2Fl\WO{ZXHz[ZMheHKxdHXpckBt\X[nbIOgc4YhfGinIGDJN2swSWu2IIDheIh4[Xl? NYLTT3J[OjR{M{KwPVk>
Huh7  M1nWV2Z2dmO2aX;uJGF{e2G7 M2nrdlPDqM7:TR?= Ml7iNUBp M{fUUZJm\HWlZYOgeIhmKH[rcoXzJIVvfHK7IHnueI8hfGinIHPlcIx{ NFzSS3EzPDF6NEG5Oi=>
A-375 M{TNe2Fxd3C2b4Ppd{BCe3OjeR?= NIT3SGg1NzhizszN NEXGOlIzPCCq M1uw[4VvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NGnpWlYzPDFzM{G3Ny=>
A-375-TS  MV3BdI9xfG:|aYOgRZN{[Xl? MnftOE85KM7:TR?= NVq4[mxsOjRiaB?= MWflcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li NXmyNoxVOjRzMUOxO|M>
Mel-HO M1XrSGFxd3C2b4Ppd{BCe3OjeR?= NF;HV4U1NzhizszN NVfGR5RVOjRiaB?= MUjlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li NXXFdnRJOjRzMUOxO|M>
Mel-HO-TS M2W5XWFxd3C2b4Ppd{BCe3OjeR?= M4XkNFQwQCEQvF2= MmHFNlQhcA>? M4P1bYVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= MVGyOFEyOzF5Mx?=
MeWo NVvZcYVOSXCxcITvd4l{KEG|c3H5 M3nJflQwQCEQvF2= MUmyOEBp MXHlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li M2rNV|I1OTF|MUez
Mel-2a MnzBRZBweHSxc3nzJGF{e2G7 M4T5UlQwQCEQvF2= NGLMb5MzPCCq MX7lcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MXKyOFEyOzF5Mx?=
MDA-MB-231 M3ziNWZ2dmO2aX;uJGF{e2G7 M4ruNFDjiJN2MECgcm0> MnXyOEBp MkKzd5VxeHKnc4Pld{BCc3RicHjvd5Bpd3K7bHH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4\VR|IzQTB4MkW5
MDA-MB-231 MWrGeY5kfGmxbjDBd5NigQ>? NX3vWItiPDByIH7N M3z5WFQhcA>? MlXB[IVkemWjc3XzJG1OWC17IHHu[EBKVC16IIDyc5RmcW5iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MkfQNlI6ODZ{NUm=
Jurkat MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXhNE4zPS1zLkK1JO69VQ>? NGGzcIIzPC92ODDo MmnNSG1UVw>? MUHpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? M4HZd|E6PzV5MUi1
Namalwa M{S3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\0S5p3OC5{NT2xMlI2KM7:TR?= MnfVNlQwPDhiaB?= M1y0OGROW09? MYfpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? M2HYRVE6PzV5MUi1
Jurkat MXfBdI9xfG:|aYOgRZN{[Xl? MYGwMlI2NTFwMkWg{txO NUTFRpE6OjRxNEigbC=> MWjEUXNQ MV7pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= NGj6fYcyQTd3N{G4OS=>
Namalwa NU[4RlNrSXCxcITvd4l{KEG|c3H5 NFvYTWcxNjJ3LUGuNlUh|ryP NYnvfoFqOjRxNEigbC=> MV;EUXNQ MlHwbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy M3jMNVE6PzV5MUi1
K562 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\oNlQhcA>? NUHJcmJ4UUN3ME2yOeKyOC5zNDDuUS=> MoX1NVk3PjJ|NkG=
SW1990 NGfEOoZHfW6ldHnvckBCe3OjeR?= MkjZNE4xOS1zIN88US=> NFG0SW4yKGh? Ml\WbY5pcWKrdIOgTGEucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v M4fhbFE6PDZ7MEKw
RT112  MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHaNVDDqM7:TR?= M1fUO|I1KGh? NXTRcVdUTE2VTx?= MX\k[YNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gS|IwVSClZXzsdy=> MXGxPFc5Pzh|Mh?=
MHG-U1 M4q1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPBTlVjOTEEoN88US=> NFjWNoozPCCq MUXEUXNQ MnnB[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJGczN01iY3XscJM> MnfONVg4QDd6M{K=
SMMC-7721 MnTjRZBweHSxc3nzJGF{e2G7 MnrCNlAxyqCwTR?= MlrjNlQhcA>? NFfp[odqdmO{ZXHz[ZMhS0i[LXnu[JVk\WRiYYDvdJRwe2m| MmPhNVc2PTdzOUG=
SMMC-7721 NFftWmNHfW6ldHnvckBCe3OjeR?= NIf4SmszODEEoH7N MmniNlQhcA>? NWjaTopGfXBvcnXneYxifGW|IN8yNUw1T1RzIHX4dJJme3Orb36= NWq4XY9bOTd3NUexPVE>
HeLa MlfRSpVv[3Srb36gRZN{[Xl? NHvjbVgyODEEoH7NxsA> NGDxTpIyKGh? NGj6UGVidHSncoOgeIhmKG2xcoDoc4xw\3lib3[geIhmKHS{YX7z[oVzemmwIILlZ5lkdGmwZzDjc41x[XK2bXXueC=> NIrIUlcyPjh7MEmxOS=>
MRC5VI MnPkSpVv[3Srb36gRZN{[Xl? NF;UXmQyOi53IH3N MXOwMlUhcA>? MXXEUXNQ MXrhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> NVG4coY1OTZ{MkezPVQ>
AT5BIVA NV3SUnVtTnWwY4Tpc44hSXO|YYm= Mny1NVIvPSCvTR?= NHnqN5MxNjViaB?= NH\3enhFVVOR NEPifVFi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? NX\jdllROTZ{MkezPVQ>
M059J M3\aeGZ2dmO2aX;uJGF{e2G7 MoW2NVIvPSCvTR?= NYS0UJR4OC53IHi= MV3EUXNQ MlrHZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> NGGwUG0yPjJ{N{O5OC=>
HeLa MmK1SpVv[3Srb36gRZN{[Xl? MUSxNk42KG2P MWKwMlUhcA>? M4fkXGROW09? NH:1V49i[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? MXWxOlIzPzN7NB?=
N2a NGT0[GxCeG:ydH;zbZMhSXO|YYm= M2r4TFAvOS1zMDFOwG0> NYi4d4RxOiCq Ml33bY5lfWOnczDk[YNz\WG|ZXSgZ4VtdCC4aXHibYxqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? M1m1XVE2QDR{N{[3
Jurkat  MmDvT4lv[XOnIFHzd4F6 NUPKOIQ1UUN3MDDv[kAzPCCwTR?= NWnQWFZGOTV4NkS1NVk>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-GSK3β / GSK3β / Bcl-xl / Bax / Caspase-3 / Cleaved caspase-3; 

PubMed: 25344912     


Four esophageal cancer cell lines were treated with different concentrations of wortmannin for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

25344912
Immunofluorescence
DNMT1; 

PubMed: 24001151     


PC3 cells were treated with DMSO or wortmannin (1 μM) for 24 hours. DNMT1 and DNMT3B cellular localization was visualized by immunofluorescent staining. After 24h of treatment, cells were fixed in methanol, incubated with the indicated antibodies, stained with Alexa Fluor 594-tagged secondary antibodies and counterstained with DAPI. Slides were then mounted and examined under a fluorescence microscope. The bright field images of PC3 cells treated with DMSO or wortmannin (1 μM) for 24 hours are shown (right panel).

24001151
Growth inhibition assay
Cell viability; 

PubMed: 25344912     


MTT assay was used to determine the effects of different concentrations of wortmannin on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

25344912
In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
- Collapse
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID